NEW YORK, May 15 – Myriad Genetics has received eight foreign patents covering the BRCA1 and BRCA2 breast and ovarian cancer genes and their use in the development of therapeutic and predictive medicine products, the company announced on Tuesday.
The European patent is for “Method for Diagnosing a Predisposition for Breast and Ovarian Cancer” using the BRCA1 and 2 genes. Four Canadian patents, two Australian, and one New Zealand patent cover the BRCA genes. Nine patents had already been issued in the United States, according to the company.
The intellectual property bears on the Salt Lake City-based company’s market position for its BRACAnalysis screening test. The diagnostic can screen for the presence of single or multi site BRAC1 and 2 susceptibility. The test is currently being marketed in Canada and Japan.
“International patents provide important protection for us and our marketing partners as we expand the availability of our predictive medicine products globally,” Peter Meldrum, CEO of Myriad Genetics, said in a statement.
Myriad also announced Tuesday a new patent issued by the US Patent and Trademark Office for the CHD1 gene, a heart disease gene involved in lipid metabolism, and for two patents for the tumor suppressor gene MTS2.